Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy

Liu, Hsin Tzu; Lin, Heng; Kuo, Hann Chorng

doi:10.1002/nau.21118

Cited by 56 publications

(40 citation statements)

References 29 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Responders to antimuscarinic therapy exhibit significantly improved urinary symptom scores and a corresponding decrease in urinary NGF levels, but the reduced NGF levels remained significantly higher than controls [21]. These authors stated that the complex pathophysiology of OAB may be multimodal and could involve several neurotransmitter and inflammatory pathways [21,25]. Our results were not compatible with the literature and changes before and after therapy in OAB-V8 and ICIQ-SF questionnaires were not correlated with NGF/Cr and fractalkine/Cr levels.…”

Section: Pol Scientificcontrasting

confidence: 91%

See 1 more Smart Citation

Data do not support the use of elevated urinary nerve growth factor and fractalkine levels as diagnostic and prognostic biomarkers for women with overactive bladder

Başok

Pelit

et al. 2015

Bladder

View full text Add to dashboard Cite

OBJECTIVE: This study investigated urinary nerve growth factor (NGF) and fractalkine levels in women with overactive bladder (OAB), as well as diagnostic and/or prognostic roles, and correlation of these urinary biomarkers with symptom severity of patients. MATERIALS AND METHODS:Twenty-seven women with OAB and 26 healthy subjects were enrolled. Patients were diagnosed with OAB based on symptoms, a 3-day voiding diary and a validated Turkish version of the Overactive Bladder-Validated 8 (OAB-V8) questionnaire. The urinary baseline levels of NGF and fractalkine were compared between OAB patients and control group. The Turkish-validated International Consultation on Incontinence Questionnaire Short Form and OAB-V8 used to categorize patients according to disease severity to assess treatment efficacy. Further urinary NGF and fractalkine levels were compared before and after antimuscarinic treatment. RESULTS:Urinary NGF/creatinine (Cr) and fractalkine/Cr were significantly elevated in OAB patients (0.40 ± 0.40 ng/ mg and 4.63 ± 4.36 ng/mg, respectively) compared to healthy subjects (0.14 ± 0.08 ng/mg and 2.00 ± 1.29 ng/mg, P = 0.002 and P = 0.005, respectively). Sensitivity and specificity were 85.2%, 65.4% for NGF, and 74.1%, 65.4% for fractalkine, respectively. No significant differences in NGF/Cr and fractalkine/Cr compared to baseline (P = 0.063 and 0.162, respectively) were observed after trospium chloride treatment in OAB patients. NGF/Cr and fractalkine/Cr exhibited no correlations with symptom severity levels. CONCLUSIONS:Increased urinary NGF/Cr and fractalkine/Cr levels were found in OAB women. However, the sensitivity and specificity were not sufficient for diagnostic use. NGF and fractalkine levels were decreased after treatment insignificantly, and there was no correlation with symptom severity; therefore their prognostic worth was limited.

show abstract

Section: Pol Scientificcontrasting

confidence: 91%

“…Therefore, increased urinary NGF levels in women refractory to antimuscarinic treatment may be related to chronic inflammation [25]. Bladder biopsies have demonstrated histological evidence of inflammatory changes in OAB in the absence of urinary tract infection [5].…”

Section: Pol Scientificmentioning

confidence: 99%

Data do not support the use of elevated urinary nerve growth factor and fractalkine levels as diagnostic and prognostic biomarkers for women with overactive bladder

Başok

Pelit

et al. 2015

Bladder

View full text Add to dashboard Cite

show abstract

“…Liu et al [24] first reported that serum NGF is also increased in some OAB patients, and according to that study, serum NGF levels were higher in patients with OAB refractory to antimuscarinic therapy. Similarly, our study evaluated the relationship between MetS and NGF levels in OAB patients, and we found that serum NGF levels were elevated in patients with both MetS and OAB compared to the levels in the controls.…”

Section: Discussionmentioning

confidence: 96%

Association between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women with Overactive Bladder

Dağdeviren

Cengiz²

2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: This study aimed to determine the association between overactive bladder (OAB), metabolic syndrome (MetS) and serum nerve growth factors (NGF). Study Design: Serum samples from a group of 90 women that included patients with OAB (group 1), patients with both OAB and MetS (group 2) and healthy women without OAB and MetS (group 3). Each group included 30 patients. Serum levels of NGF were compared among the groups. Results: When the groups were compared with respect to NGF levels, group 2 was found to have significantly higher NGF levels (p = 0.001). A NGF threshold of >380 ng/mL had a sensitivity of 81.7% and a specificity of 100% to discriminate between groups 2 and 3. Conclusion: Our findings support the theory that possible sympathetic overactivity, proinflammatory status, oxidative stress and other pathological conditions associated with MetS and potentially involved in the development of OAB lead to increased serum NGF levels. These findings may help to shed light on the complicated pathogenesis of OAB.

show abstract

“…Liu et al [40] noted that the serum concentrations of CRP, NGF, IL-1β, IL-6, IL-8, and TNF-α in OAB-dry and OAB-wet study participants were significantly higher than among the controls.…”

Section: Brain-derived Nerve Growth Factormentioning

confidence: 99%

Urinary Biomarkers Under Investigation for Overactive Bladder Syndrome

Guirguis

Heit

2015

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Overactive bladder (OAB) is a symptom syndrome of urinary urgency, frequency, nocturia, and urge incontinence suggestive of lower urinary tract dysfunction. Detrusor overactivity (DO) during urodynamic testing may be the cause of symptoms in 54-70% of OAB study participants.The identification of urinary biomarkers is warranted due to the high false negative rate of urodynamic testing results for the diagnosis of DO and for the evaluation of treatment response in study participants with OAB symptoms.We reviewed the published literature on urinary biomarkers under investigation for OAB with Pub Med up to June 2015 using search keywords that included: "overactive bladder", "nerve growth factor (NGF)", "brain derived nerve growth factor (BDNF)", "prostaglandins", "cytokines" and "CRP".Current evidence suggests that NGF and BDNF appear to be most promising candidates for urinary biomarkers for the diagnosis and the evaluation treatment response.3

show abstract

Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy

Abstract: Increased serum and urinary NGF levels in patients with OAB refractory to antimuscarinic treatment suggest these bladder disorders might be caused by chronic inflammation.

Cited by 56 publications

References 29 publications

Data do not support the use of elevated urinary nerve growth factor and fractalkine levels as diagnostic and prognostic biomarkers for women with overactive bladder

Data do not support the use of elevated urinary nerve growth factor and fractalkine levels as diagnostic and prognostic biomarkers for women with overactive bladder

Association between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women with Overactive Bladder

Urinary Biomarkers Under Investigation for Overactive Bladder Syndrome

Contact Info

Product

Resources

About